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Heart Failure With
Preserved Ejection Fraction
A Heterogenous Disorder With
Multifactorial Pathophysiology*
Dalane W. Kitzman, MD, Bharathi Upadhya, MD
Winston-Salem, North Carolina
Heart failure (HF) with preserved ejection fraction
(HFpEF) is the most common form of HF in the pop-
ulation (1). Among elderly women living in the community,
HFpEF comprises nearly 90% of incident HF cases (2).
Furthermore, HFpEF is increasing out of proportion to
HF with reduced EF (HFrEF), and its prognosis is wors-
ening while that of HFrEF is improving (3). The health
and economic impact of HFpEF is at least as great as that
of HFrEF, with similar severity of chronic exercise intoler-
ance (4), acute hospitalization rates (3,5), and substantial
mortality (3).
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Despite the importance of HFpEF, our understanding of
its pathophysiology is incomplete, and optimal treatment
remains largely undeﬁned. Originally thought to be purely
due to left ventricular (LV) diastolic dysfunction (hence the
now-discarded misnomer “diastolic HF”), it is now obvious
that HFpEF is much more complex. Findings to date in-
dicate important contributions from aging (6,7), neuroendo-
crine dysfunction (4,8), inﬂammation (9,10), LV systolic
dysfunction (11,12) right ventricular dysfunction (13), chro-
notropic incompetence (14), autonomic dysfunction (15),
vascular dysfunction (15–17), pulmonary and renal dysfunction
(1,2,18), skeletal muscle dysfunction (19–21), and multiple
comorbidities (22) including obesity, hypertension, atrial
ﬁbrillation, and anemia. Although this complexity presents
challenges, it also presents opportunities for advancing our
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trials to date, which were based upon our previous, simplistic
assumptions, have not been positive.
The results of the exemplary study by Kraigher-Krainer
et al. (12) reported in this issue of the Journal provide addi-
tional strong support for the concepts of phenotypic hetero-
geneity and multifactorial contributions in the HFpEF
syndrome. Their well-designed, well-conducted ancillary
study utilized a standardized protocol with state-of-the art,
detailed echo-Doppler measures of cardiac structure and
function, formal training of sonographers at 65 ﬁeld sites,
and expert, blinded quantitative image analysis, all orches-
trated by a highly experienced echocardiographic core labo-
ratory (12). Systolic function was assessed as longitudinal
and circumferential strain by deformation analysis using
2-dimensional digital echocardiography speckle-tracking.
This method has advantages over tissue Doppler strain
methods and is more amenable to multisite trials involving
multiple ultrasonographic instrument vendors. The investi-
gators further enhanced the study by including 2 age-
matched control groupsdnormal subjects and patients with
hypertension.
Despite relatively preserved ejection fraction, both longi-
tudinal and circumferential strain were signiﬁcantly reduced
in HFpEF patients compared to both control groups (12).
Longitudinal strain was the most abnormal. Reduced lon-
gitudinal strain was most common in the HFpEF patients
within the lower EF range (45% to 54%) but was present
in 50% of patients within the normal EF range. Reduced
strain was present even after excluding patients with
ischemic heart disease. Reduced strain was associated with
acute hospitalization and higher N-terminal pro-brain
natriuretic peptide (NT-proBNP) levels.
These data indicate that systolic dysfunction is common
in HFpEF and likely contributes to its pathophysiology
and poor outcomes. Kraigher-Krainer et al. (12) performed
measurements only at rest and in stable outpatients. Previous
studies of exercise intolerance (23,24) and acute pulmonary
edema (25), the 2 key manifestations of HFpEF, have not
found contributions from traditional measures of systolic
dysfunction. However, Henein et al. (26) found that failure
to increase longitudinal strain during exercise contributes to
exercise intolerance.
These ﬁndings should not be surprising. LV relaxation
and contraction are intimately related; both are dependent
upon availability of adenosine triphosphate and modulated
by adrenergic stimulation. Studies of HFrEF established
long ago that systolic dysfunction is rarely present without
concomitant diastolic dysfunction. The present study further
promotes the concept of generalized cardiac dysfunction in
HF, even when EF is apparently preserved.
The therapeutic implications are confounded by trial
experience involving HFrEF patients, in whom inotropes
improve systolic function and exercise capacity but in-
crease mortality. Beta-blockers, which are negative inotropes
(and negative lusitropes), paradoxically reduce mortality.
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458Manipulating LV systolic and diastolic function to improve
outcomes in HF patients has proved more challenging than
anticipated.
The present study (12) had several other important
ﬁndings: only 8% of patients had LV hypertrophy; only 15%
had concentric remodeling; Doppler tissue diastolic veloci-
ties were only mildly lower than normal subjects and similar
to hypertensive subjects; end-diastolic volume was larger
than both normal and hypertension controls; systolic and
diastolic blood pressure were controlled; and left atrial
pressure was frankly increased in <50% of patients. These
ﬁndings occurred despite stringent inclusion criteria,
including severely increased NT-proBNP. Other studies,
including population-based studies less inﬂuenced by trial
selection criteria, have had similar ﬁndings (18,24,27). Thus,
in stark contrast to earlier paradigms, many stable outpa-
tients with HFpEF, in some cases the majority, do not
have LV hypertrophy, concentric remodeling, uncontrolled
hypertension, elevated left atrial pressure, or abnormal dia-
stolic ﬁlling, and do have LV dilation, reduced systolic
function, and a variety of noncardiovascular abnormalities.
The presence of phenotypic heterogeneity, multifactorial
pathophysiology, and multiorgan involvement in HFpEF
should not be surprising. These features are also seen in
HFrEF, and reﬂect HF as a systemic disorder. They are also
typical of other disorders common in the elderly. HFpEF is
strongly inﬂuenced by aging, a systemic process affecting all
organ systems (6,7). The impact of multiple comorbidities
typical of older HFpEF patients further ensures phenotypic
heterogeneity and multifactorial pathophysiology (22).
A broader, systemic view of HFpEF also helps explain
observations that nearly two-thirds of subsequent hospital-
izations are non-HF related and approximately 50% are
noncardiac (5), that the majority of HFpEF patients die of
noncardiovascular causes (28), and that the large HFpEF
pharmacological trials to date, which were based on earlier
simplistic paradigms, have not been positive.
Progress in HFpEF will be made by incorporating these
concepts of heterogeneity and multifactorial contributions,
and searching for the common threads and links with other
debilitating disorders common among the elderly (29). For
example, recent parabiosis studies show that signaling factors
in the circulation can reverse or accelerate key features of
cardiovascular aging related to HFpEF (30). Key ﬁndings
such as this further support that HF in the elderly is
a systemic process, and could increase understanding of
the fundamental pathophysiology of HFpEF and lead to
development of novel strategies for its prevention and
treatment.
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